[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019007968A - Compuestos medicinales y suplementos nutricionales. - Google Patents

Compuestos medicinales y suplementos nutricionales.

Info

Publication number
MX2019007968A
MX2019007968A MX2019007968A MX2019007968A MX2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A
Authority
MX
Mexico
Prior art keywords
nutritional supplements
medicinal compounds
carriers
various
carrier combinations
Prior art date
Application number
MX2019007968A
Other languages
English (en)
Inventor
Leone-Bay Andrea
WESNER Gregory
Original Assignee
Receptor Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62790943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019007968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Receptor Holdings Inc filed Critical Receptor Holdings Inc
Publication of MX2019007968A publication Critical patent/MX2019007968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos medicinales o suplementos nutricionales de cannabinoide sintético en diversas combinaciones de portador. Los portadores pueden incluir aminoácidos grasos N-acilados, potenciadores de penetración y/o diversos otros portadores favorables. Las combinaciones de portador/composición de cannabinoide sintético pueden crear beneficios de administración.
MX2019007968A 2017-01-03 2018-01-03 Compuestos medicinales y suplementos nutricionales. MX2019007968A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762441908P 2017-01-03 2017-01-03
PCT/US2018/012261 WO2018129097A1 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements

Publications (1)

Publication Number Publication Date
MX2019007968A true MX2019007968A (es) 2019-12-05

Family

ID=62790943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007968A MX2019007968A (es) 2017-01-03 2018-01-03 Compuestos medicinales y suplementos nutricionales.

Country Status (14)

Country Link
US (2) US20190336472A1 (es)
EP (1) EP3565539A4 (es)
JP (3) JP7281815B2 (es)
KR (1) KR20190103302A (es)
CN (1) CN110121337A (es)
AU (2) AU2018206564B2 (es)
BR (1) BR112019013743A2 (es)
CA (1) CA3049226A1 (es)
CL (1) CL2019001832A1 (es)
CO (1) CO2019008176A2 (es)
EA (1) EA201991641A1 (es)
IL (1) IL267831A (es)
MX (1) MX2019007968A (es)
WO (1) WO2018129097A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180781B2 (en) * 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
MX2019007968A (es) * 2017-01-03 2019-12-05 Receptor Holdings Inc Compuestos medicinales y suplementos nutricionales.
CA3089750A1 (en) * 2018-01-29 2019-08-01 Solantech Inc. Methods of treating and/or preventing bedsores using nabilone
BR112021006858A2 (pt) * 2018-10-10 2021-07-13 Tilray Inc. métodos e formulações para tratar náusea e vômito induzidos por quimioterapia
MX2021005807A (es) 2018-11-19 2021-07-02 Receptor Holdings Inc Aminoacidos grasos n-acilados para reducir la variabilidad de absorcion en composiciones basadas en cannabinoides.
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
JP2022547409A (ja) 2019-08-30 2022-11-14 サクソー 充填顆粒、これらの製造方法及びこれらの使用
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
CN113040337B (zh) * 2021-04-22 2022-12-09 四川大学 一种熏肉制品及其制备方法
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008490A1 (en) 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
ES2536922T3 (es) 2006-09-15 2015-05-29 Echo Pharmaceuticals B.V. Unidad de dosificación para administración sublingual, bucal u oral de sustancias farmacéuticamente activas insolubles en agua
AU2011333683A1 (en) * 2010-11-25 2013-05-09 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
WO2013032934A1 (en) * 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
MX2019007968A (es) * 2017-01-03 2019-12-05 Receptor Holdings Inc Compuestos medicinales y suplementos nutricionales.

Also Published As

Publication number Publication date
EP3565539A1 (en) 2019-11-13
JP2023071697A (ja) 2023-05-23
JP7281815B2 (ja) 2023-05-26
CA3049226A1 (en) 2018-07-12
CL2019001832A1 (es) 2020-01-31
CO2019008176A2 (es) 2019-08-20
AU2024201078A1 (en) 2024-03-07
US20190336472A1 (en) 2019-11-07
BR112019013743A2 (pt) 2020-01-21
WO2018129097A1 (en) 2018-07-12
AU2018206564A1 (en) 2019-08-15
JP2024075724A (ja) 2024-06-04
JP7466238B2 (ja) 2024-04-12
IL267831A (en) 2019-09-26
CN110121337A (zh) 2019-08-13
AU2018206564B2 (en) 2023-12-07
EA201991641A1 (ru) 2020-03-10
KR20190103302A (ko) 2019-09-04
US20230293479A1 (en) 2023-09-21
JP2020503357A (ja) 2020-01-30
EP3565539A4 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
MX2021006037A (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion.
MX2019007968A (es) Compuestos medicinales y suplementos nutricionales.
CO2019005565A2 (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
MX2020003330A (es) Composiciones de hierbas con mejor biodisponibilidad.
SG11201907321TA (en) Anti-gprc5d antibody and molecule comprising the antibody
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
CL2020000909A1 (es) Formulaciones cannabinoides sintéticas y basadas en plantas de rapido inicio y de acción prolongada.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2021003678A (es) Vehiculo aislado para articulos con temperatura controlada.
EP4424368A3 (en) Compositions comprising an urolithin compound
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
GB2569073A (en) Animal feed supplement
PH12016501947A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
UY4753S (es) Configuracion aplicada en maquina de bebidas
PH12018500165A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
PH12018500164A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
BR112018001719A2 (pt) composição farmacêutica com micela polimérica, e, método para preparação de uma composição farmacêutica com micela polimérica.
UA92914U (uk) Антиоксидантний та імуномодулюючий препарат "селцивіт"
MX2019014359A (es) Composicion colorante que comprende fosfato tricalcico como agente colorante blanco.
PH12018500168A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها
UA104329U (uk) Комплексна харчова добавка на основі тваринної та рослинної сировини
NZ752367A (en) Nitrogen utilisation modulation
UA95002U (xx) Кормова добавка з пребіотичною дією "пребіолакт"
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina